Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.65
INSM's Cash-to-Debt is ranked lower than
70% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. INSM: 1.65 )
Ranked among companies with meaningful Cash-to-Debt only.
INSM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.86  Med: 13.48 Max: No Debt
Current: 1.65
Debt-to-Equity 0.66
INSM's Debt-to-Equity is ranked lower than
64% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. INSM: 0.66 )
Ranked among companies with meaningful Debt-to-Equity only.
INSM' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.75  Med: 0.13 Max: 3.85
Current: 0.66
-0.75
3.85
Piotroski F-Score: 1
Altman Z-Score: 5.13
Beneish M-Score: -4.55
WACC vs ROIC
13.04%
-368.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE % -113.68
INSM's ROE % is ranked lower than
74% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. INSM: -113.68 )
Ranked among companies with meaningful ROE % only.
INSM' s ROE % Range Over the Past 10 Years
Min: -361.62  Med: -44.96 Max: 195.47
Current: -113.68
-361.62
195.47
ROA % -79.73
INSM's ROA % is ranked lower than
75% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. INSM: -79.73 )
Ranked among companies with meaningful ROA % only.
INSM' s ROA % Range Over the Past 10 Years
Min: -129.17  Med: -37.18 Max: 180.06
Current: -79.73
-129.17
180.06
ROC (Joel Greenblatt) % -1861.61
INSM's ROC (Joel Greenblatt) % is ranked lower than
69% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. INSM: -1861.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INSM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -720550  Med: -2254.29 Max: -1133.76
Current: -1861.61
-720550
-1133.76
3-Year Revenue Growth Rate -100.00
INSM's 3-Year Revenue Growth Rate is ranked lower than
94% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. INSM: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INSM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.3 Max: 481.9
Current: -100
0
481.9
3-Year EBITDA Growth Rate 21.10
INSM's 3-Year EBITDA Growth Rate is ranked higher than
74% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. INSM: 21.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INSM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -59.4  Med: -15.9 Max: 49.2
Current: 21.1
-59.4
49.2
3-Year EPS without NRI Growth Rate 21.20
INSM's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. INSM: 21.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INSM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.5  Med: -14.6 Max: 48.4
Current: 21.2
-59.5
48.4
GuruFocus has detected 3 Warning Signs with Insmed Inc $INSM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INSM's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

INSM Guru Trades in Q3 2016

Jim Simons 197,700 sh (+32.42%)
John Paulson 205,200 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones 23,036 sh (-18.20%)
» More
Q4 2016

INSM Guru Trades in Q4 2016

John Paulson 205,200 sh (unchged)
Paul Tudor Jones 22,887 sh (-0.65%)
Jim Simons 120,500 sh (-39.05%)
» More
Q1 2017

INSM Guru Trades in Q1 2017

Steven Cohen 50,000 sh (New)
Jim Simons Sold Out
Paul Tudor Jones 15,667 sh (-31.55%)
John Paulson 90,000 sh (-56.14%)
» More
Q2 2017

INSM Guru Trades in Q2 2017

Louis Moore Bacon 25,000 sh (New)
Paul Tudor Jones 21,622 sh (+38.01%)
John Paulson Sold Out
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INSM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Sold Out 0.02%$15.18 - $19.23 $ 28.4867%0
John Paulson 2017-03-31 Reduce -56.14%0.02%$13.08 - $17.51 $ 28.4885%90,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CORT, NAS:BPMC, NAS:FOLD, NAS:HALO, NAS:RGEN, NYSE:XON, NAS:SAGE, NAS:RARE, NAS:ARRY, NAS:ICPT, NYSE:CBM, NAS:MYOK, NAS:LOXO, NAS:AKCA, NYSE:EBS, NAS:XLRN, NAS:INVA, NAS:AVXS, NAS:LGND, NYSE:BHVN » details
Traded in other countries:IM8N.Germany,
Headquarter Location:USA
Insmed Inc is a global biotechnology company. It is focused on developing novel therapies that focus primarily on lung diseases.

Insmed Inc is a global biotechnology company that is focused on developing novel therapies for rare diseases. The company works to develop and commercialize therapies that focus primarily on lung diseases. Insmed is focused broadly on rare disease therapeutics and prioritizing its current therapeutic focus in the fields of pulmonology and infectious disease. The company's strategy includes licensing its patents and pending patent applications. The company's primary businesses are within the U.S., Europe, and Canada, while also maintaining operations in other international markets as well.

Top Ranked Articles about Insmed Inc

Insmed to Present at Two September Investor Conferences
As Insmed Reaches New Highs, Is Matinas Following in Its Footsteps? Matinas, working on a version of Insmed drug, may now be in a position to duplicate its success
Pharmaceutical firm Insmed Inc. (NASDAQ:INSM) was nearing new all-time highs again as markets continued to digest the surprisingly good news last week that its lead drug Arikayce succeeded in Phase 3 trials. Arikayce is an inhalable version of the antibiotic amikacin for nontuberculous mycobacteria. The news initially brought shares up 108% overnight, and they continue to edge higher this week. Read more...
Insmed Announces Closing of Public Offering
Insmed Announces Pricing of Public Offering of Common Stock
Get A Stock Report On Disney, The Goldman Sachs Group, Hewlett Packard Enterprise Company, Insmed inc., Trivago, Or Any Stock You Choose.
Insmed Announces Proposed Public Offering of Common Stock
Shares of Insmed More Than Double Company's shares skyrocketing on positive clinical news
While Federal Reserve Gov. Lael Brainard said the U.S. central bank should focus on underlying inflation before raising interest rates again after a series of weak records, it would be prudent to raise the federal funds rate more gradually if inflation is below the 2% target. Read more...
Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)
Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017
Insmed to Host Analyst and Investor Day on July 19, 2017

Ratios

vs
industry
vs
history
PB Ratio 21.28
INSM's PB Ratio is ranked lower than
79% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. INSM: 21.28 )
Ranked among companies with meaningful PB Ratio only.
INSM' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 3.89 Max: 105
Current: 21.28
0.45
105
EV-to-EBIT -11.72
INSM's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. INSM: -11.72 )
Ranked among companies with meaningful EV-to-EBIT only.
INSM' s EV-to-EBIT Range Over the Past 10 Years
Min: -34.1  Med: -4.3 Max: 163.9
Current: -11.72
-34.1
163.9
EV-to-EBITDA -11.90
INSM's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. INSM: -11.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
INSM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -66.8  Med: -4.55 Max: 317.3
Current: -11.9
-66.8
317.3
Current Ratio 3.67
INSM's Current Ratio is ranked higher than
61% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. INSM: 3.67 )
Ranked among companies with meaningful Current Ratio only.
INSM' s Current Ratio Range Over the Past 10 Years
Min: 0.53  Med: 7.23 Max: 54.49
Current: 3.67
0.53
54.49
Quick Ratio 3.67
INSM's Quick Ratio is ranked higher than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. INSM: 3.67 )
Ranked among companies with meaningful Quick Ratio only.
INSM' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 7.23 Max: 54.49
Current: 3.67
0.53
54.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.60
INSM's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. INSM: -16.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INSM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -119  Med: -26.1 Max: -5.4
Current: -16.6
-119
-5.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 203.43
INSM's Price-to-Net-Cash is ranked lower than
81% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. INSM: 203.43 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INSM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.57  Med: 4.71 Max: 203.71
Current: 203.43
0.57
203.71
Price-to-Net-Current-Asset-Value 123.83
INSM's Price-to-Net-Current-Asset-Value is ranked lower than
82% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. INSM: 123.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INSM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.52  Med: 4.61 Max: 156.67
Current: 123.83
0.52
156.67
Price-to-Tangible-Book 69.46
INSM's Price-to-Tangible-Book is ranked lower than
86% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. INSM: 69.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INSM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.51  Med: 4.39 Max: 85
Current: 69.46
0.51
85
Earnings Yield (Greenblatt) % -8.51
INSM's Earnings Yield (Greenblatt) % is ranked lower than
69% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. INSM: -8.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INSM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8315.3  Med: -14.35 Max: 15132.8
Current: -8.51
-8315.3
15132.8

More Statistics

EPS (TTM) $ -3.04
Beta1.82
Short Percentage of Float9.96%
52-Week Range $10.21 - 31.39
Shares Outstanding (Mil)76.50

Analyst Estimate

Dec17 Dec19 Dec20
Revenue (Mil $) 191 411
EPS ($) -2.45 0.23 2.08
EPS without NRI ($) -2.45 0.23 2.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for INSM

Headlines

Articles On GuruFocus.com
As Insmed Reaches New Highs, Is Matinas Following in its Footsteps? Sep 12 2017 
Insmed Announces Closing of Public Offering Sep 11 2017 
Insmed Announces Pricing of Public Offering of Common Stock Sep 06 2017 
Get A Stock Report On Disney, The Goldman Sachs Group, Hewlett Packard Enterprise Company, Insmed in Sep 06 2017 
Insmed Announces Proposed Public Offering of Common Stock Sep 05 2017 
Shares of Insmed More Than Double Sep 05 2017 
Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inh Sep 05 2017 
Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017 Jul 27 2017 
Insmed to Host Analyst and Investor Day on July 19, 2017 Jul 12 2017 
Insmed to Present at the JMP Securities Life Sciences Conference Jun 13 2017 

More From Other Websites
Insmed to Present at Two September Investor Conferences Sep 19 2017
As Insmed Reaches New Highs, Is Matinas Following in Its Footsteps? Sep 12 2017
Insmed Announces Closing of Public Offering Sep 11 2017
See what the IHS Markit Score report has to say about Insmed Inc. Sep 11 2017
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher? Sep 09 2017
Insmed Announces Pricing of Public Offering of Common Stock Sep 06 2017
How Insmed Is Capitalizing on Its Huge Late-Stage Success Sep 06 2017
Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6% Sep 06 2017
Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data Sep 06 2017
Today's Research Reports on Stocks to Watch: Insmed Inc. and XOMA Corporation Sep 06 2017
Could These 2 Biotech Stocks Really Double Your Money? Sep 06 2017
Biotech stock doubles in single day after treatment for a rare lung disease has successful trial Sep 05 2017
Why Insmed, Himax Technologies, and Yamana Gold Jumped Today Sep 05 2017
Insmed Announces Proposed Public Offering of Common Stock Sep 05 2017
Insmed soars on positive lung drug study results Sep 05 2017
Here's Why Insmed Incorporated Is Skyrocketing Sep 05 2017
Why Did Insmed (INSM) Stock Skyrocket Today? Sep 05 2017
United Tech, Rockwell combo, Tronc buys Daily News, Disney gets upgraded Sep 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}